The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 173-185

  O'Leary, Erin M ^a   Igdoura, Suleiman A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Celastrol; Enzyme enhancement treatment; Gangliosides; Lysosomal Storage Disorder; MG 132; Sialidosis

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CELASTROL; GANGLIOSIDE GD3; GANGLIOSIDE GM3; GANGLIOSIDE GT 1B; SIALIDASE;

ARTICLE; CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LOCALIZATION; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIALIDOSIS;

CELL LINE; CYSTEINE PROTEINASE INHIBITORS; ENZYME ACTIVATION; FIBROBLASTS; GANGLIOSIDES; GENE EXPRESSION REGULATION; HUMANS; LEUPEPTINS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; MUCOLIPIDOSES; MUTATION; NEURAMINIDASE; PROTEIN BINDING; PROTEIN TRANSPORT; TRITERPENES;

EID: 84866156846     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.07.013     Document Type: Article

References (77)

1. Bonten E., van der Spoel A., Fornerod M., Grosveld G., d'Azzo A. Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 1996, 10:3156-3169.
2. Cantz M., Gehler J., Spranger J. Mucolipidosis i: increased sialic acid content and deficiency of an alpha-n-acetylneuraminidase in cultured fibroblasts. Biochem. Biophys. Res. Commun. 1977, 74:732-738.
3. Igdoura S.A., Argraves W.S., Morales C.R. Low density lipoprotein receptor-related protein-1 expression in the testis: regulated expression in Sertoli cells. J. Androl. 1997, 18:400-410.
4. Saito M., Yu R. Biology of the Sialic Acids 1995, Plenum Press, New York, NY, p. 261-313.
5. Lowden J.A., O'Brien J.S. Sialidosis: a review of human neuraminidase deficiency. Am. J. Hum. Genet. 1979, 31:1-18.
6. Wu X., Steigelman K.A., Bonten E., Hu H., He W., Ren T., Zuo J., d'Azzo A. Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1-deficient mice. Biochim. Biophys. Acta 2010, 1802:259-268.
7. Durand P., Gatti R., Cavalieri S., Borrone C., Tondeur M., Michalski J.C., Strecker G. Sialidosis (mucolipidosis i). Helv. Paediatr. Acta 1977, 32:391-400.
8. Rapin I., Goldfischer S., Katzman R., Engel J., O'Brien J.S. The cherry-red spot-myoclonus syndrome. Ann. Neurol. 1978, 3:234-242.
9. Kelly T.E., Graetz G. Isolated acid neuraminidase deficiency: a distinct lysosomal storage disease. Am. J. Med. Genet. 1977, 1:31-46.
10. Spranger J., Cantz M. Mucolipidosis i, the cherry red-spot-myoclonus syndrome and neuraminidase deficiency. Birth Defects Orig. Artic. Ser. 1978, 14:105-112.
11. Spranger J.W., Wiedemann H.R. The genetic mucolipidoses. Diagnosis and differential diagnosis. Humangenetik 1970, 9:113-139.
12. Beck M., Bender S.W., Reiter H.L., Otto W., Bässler R., Dancygier H., Gehler J. Neuraminidase deficiency presenting as non-immune hydrops fetalis. Eur. J. Pediatr. 1984, 143:135-139.
13. Tylki-Szymanska A., Lugowska A., Czartoryska B. Neuraminidase deficiency presenting as a nephrosialidosis: the first case detected in Poland. Acta Paediatr. Jpn. 1996, 38:529-532.
14. Pshezhetsky A.V., Richard C., Michaud L., Igdoura S., Wang S., Elsliger M.A., Qu J., Leclerc D., Gravel R., Dallaire L., Potier M. Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat. Genet. 1997, 15:316-320.
15. Monti E., Preti A., Rossi E., Ballabio A., Borsani G. Cloning and characterization of neu2, a human gene homologous to rodent soluble sialidases. Genomics 1999, 57:137-143.
16. Monti E., Bassi M.T., Papini N., Riboni M., Manzoni M., Venerando B., Croci G., Preti A., Ballabio A., Tettamanti G., Borsani G. Identification and expression of neu3, a novel human sialidase associated to the plasma membrane. Biochem. J. 2000, 349:343-351.
17. Monti E., Bassi M.T., Bresciani R., Civini S., Croci G.L., Papini N., Riboni M., Zanchetti G., Ballabio A., Preti A., Tettamanti G., Venerando B., Borsani G. Molecular cloning and characterization of neu4, the fourth member of the human sialidase gene family. Genomics 2004, 83:445-453.
18. Yamaguchi K., Hata K., Koseki K., Shiozaki K., Akita H., Wada T., Moriya S., Miyagi T. Evidence for mitochondrial localization of a novel human sialidase (neu4). Biochem. J. 2005, 390:85-93.
19. Lukong K.E., Elsliger M.A., Chang Y., Richard C., Thomas G., Carey W., Tylki-Szymanska A., Czartoryska B., Buchholz T., Criado G.R., Palmeri S., Pshezhetsky A.V. Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex. Hum. Mol. Genet. 2000, 9:1075-1085.
20. Monti E., Bonten E., D'Azzo A., Bresciani R., Venerando B., Borsani G., Schauer R., Tettamanti G. Sialidases in vertebrates: a family of enzymes tailored for several cell functions. Adv. Carbohydr. Chem. Biochem. 2010, 64:403-479.
21. Quistgaard E.M., Thirup S.S. Sequence and structural analysis of the asp-box motif and asp-box beta-propellers; a widespread propeller-type characteristic of the vps10 domain family and several glycoside hydrolase families. BMC Struct. Biol. 2009, 9:46.
22. Igdoura S.A., Mertineit C., Trasler J.M., Gravel R.A. Sialidase-mediated depletion of gm2 ganglioside in Tay-Sachs neuroglia cells. Hum. Mol. Genet. 1999, 8:1111-1116.
23. Amith S.R., Jayanth P., Franchuk S., Finlay T., Seyrantepe V., Beyaert R., Pshezhetsky A.V., Szewczuk M.R. Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of toll-like receptor 4 is essential for receptor activation and cellular signaling. Cell. Signal. 2010, 22:314-324.
24. Hinek A., Pshezhetsky A.V., von Itzstein M., Starcher B. Lysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assembly. J. Biol. Chem. 2006, 281:3698-3710.
25. Lukong K.E., Seyrantepe V., Landry K., Trudel S., Ahmad A., Gahl W.A., Lefrancois S., Morales C.R., Pshezhetsky A.V. Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail. J. Biol. Chem. 2001, 276:46172-46181.
26. Starcher B., d'Azzo A., Keller P.W., Rao G.K., Nadarajah D., Hinek A. Neuraminidase-1 is required for the normal assembly of elastic fibers. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L637-L647.
27. Bonten E.J., Campos Y., Zaitsev V., Nourse A., Waddell B., Lewis W., Taylor G., d'Azzo A. Heterodimerization of the sialidase neu1 with the chaperone protective protein/cathepsin a prevents its premature oligomerization. J. Biol. Chem. 2009, 284:28430-28441.
28. Bonten E.J., Galjart N.J., Willemsen R., Usmany M., Vlak J.M., d'Azzo A. Lysosomal protective protein/cathepsin a. role of the "linker" domain in catalytic activation. J. Biol. Chem. 1995, 270:26441-26445.
29. Lukong K.E., Landry K., Elsliger M.A., Chang Y., Lefrancois S., Morales C.R., Pshezhetsky A.V. Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex. J. Biol. Chem. 2001, 276:17286-17290.
30. Seyrantepe V., Poupetova H., Froissart R., Zabot M.-T., Maire I., Pshezhetsky A.V. Molecular pathology of neu1 gene in sialidosis. Hum. Mutat. 2003, 22:343-352.
31. Albohy A., Li M.D., Zheng R.B., Zou C., Cairo C.W. Insight into substrate recognition and catalysis by the human neuraminidase 3 (neu3) through molecular modeling and site-directed mutagenesis. Glycobiology 2010, 20:1127-1138.
32. Itoh K., Naganawa Y., Matsuzawa F., Aikawa S., Doi H., Sasagasako N., Yamada T., ichi Kira J., Kobayashi T., Pshezhetsky A.V., Sakuraba H. Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes. J. Hum. Genet. 2002, 47:29-37.
33. Magesh S., Suzuki T., Miyagi T., Ishida H., Kiso M. Homology modeling of human sialidase enzymes neu1, neu3 and neu4 based on the crystal structure of neu2: hints for the design of selective neu3 inhibitors. J. Mol. Graph. Model. 2006, 25:196-207.
34. Pattison S., Pankarican M., Rupar C.A., Graham F.L., Igdoura S.A. Five novel mutations in the lysosomal sialidase gene (neu1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression. Hum. Mutat. 2004, 23:32-39.
35. Mu T.-W., Ong D.S.T., Wang Y.-J., Balch W.E., Yates J.R., Segatori L., Kelly J.W. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008, 134:769-781.
36. Lee D.H., Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998, 8:397-403.
37. Crawford L.J.A., Walker B., Ovaa H., Chauhan D., Anderson K.C., Morris T.C.M., Irvine A.E. Comparative selectivity and specificity of the proteasome inhibitors bzlllcocho, ps-341, and mg-132. Cancer Res. 2006, 66:6379-6386.
38. Bush K.T., Goldberg A.L., Nigam S.K. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J. Biol. Chem. 1997, 272:9086-9092.
39. Salminen A., Lehtonen M., Paimela T., Kaarniranta K. Celastrol: molecular targets of thunder god vine. Biochem. Biophys. Res. Commun. 2010, 394:439-442.
40. Westerheide S.D., Bosman J.D., Mbadugha B.N.A., Kawahara T.L.A., Matsumoto G., Kim S., Gu W., Devlin J.P., Silverman R.B., Morimoto R.I. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 2004, 279:56053-56060.
41. Chen G., Cao P., Goeddel D.V. Tnf-induced recruitment and activation of the ikk complex require cdc37 and hsp90. Mol. Cell 2002, 9:401-410.
42. Paris D., Ganey N.J., Laporte V., Patel N.S., Beaulieu-Abdelahad D., Bachmeier C., March A., Ait-Ghezala G., Mullan M.J. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 2010, 7:17.
43. Igdoura S.A., Gafuik C., Mertineit C., Saberi F., Pshezhetsky A.V., Potier M., Trasler J.M., Gravel R.A. Cloning of the cdna and gene encoding mouse lysosomal sialidase and correction of sialidase deficiency in human sialidosis and mouse sm/j fibroblasts. Hum. Mol. Genet. 1998, 7:115-121.
44. Zinchuk V., Zinchuk O., Okada T. Quantitative colocalization analysis of multicolor confocal immunofluorescence microscopy images: pushing pixels to explore biological phenomena. Acta Histochem. Cytochem. 2007, 40:101-111.
45. Elangovan M., Oh C., Sukumaran L., Wójcik C., Yoo Y.J. Functional differences between two major ubiquitin receptors in the proteasome; s5a and hrpn13. Biochem. Biophys. Res. Commun. 2010, 396:425-428.
46. Cantz M., Gehler J. The mucopolysaccharidoses: inborn errors of glycosaminoglycan catabolism. Hum. Genet. 1976, 32:233-255.
47. Bonten E.J., Arts W.F., Beck M., Covanis A., Donati M.A., Parini R., Zammarchi E., d'Azzo A. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum. Mol. Genet. 2000, 9:2715-2725.
48. Monti E., Preti A., Venerando B., Borsani G. Recent development in mammalian sialidase molecular biology. Neurochem. Res. 2002, 27:649-663.
49. Gidalevitz T., Kikis E.A., Morimoto R.I. A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr. Opin. Struct. Biol. 2010, 20:23-32.
50. Heese B.A. Current strategies in the management of lysosomal storage diseases. Semin. Pediatr. Neurol. 2008, 15:119-126.
51. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum. Genet. 2007, 121:1-22.
52. Cohen F.E., Kelly J.W. Therapeutic approaches to protein-misfolding diseases. Nature 2003, 426:905-909.
53. Sawkar A.R., D'Haeze W., Kelly J.W. Therapeutic strategies to ameliorate lysosomal storage disorders-a focus on gaucher disease. Cell. Mol. Life Sci. 2006, 63:1179-1192.
54. Wang D., Zaitsev S., Taylor G., d'Azzo A., Bonten E. Protective protein/cathepsin a rescues n-glycosylation defects in neuraminidase-1. Biochim. Biophys. Acta 2009, 1790(4):275-282.
55. Powers E.T., Morimoto R.I., Dillin A., Kelly J.W., Balch W.E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 2009, 78:959-991.
56. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on mhc class i molecules. Cell 1994, 78:761-771.
57. Mishra A., Godavarthi S.K., Maheshwari M., Goswami A., Jana N.R. The ubiquitin ligase e6-ap is induced and recruited to aggresomes in response to proteasome inhibition and may be involved in the ubiquitination of hsp70-bound misfolded proteins. J. Biol. Chem. 2009, 284:10537-10545.
58. Walcott S.E., Heikkila J.J. Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis a6 cells. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2010, 156:285-293.
59. Yu Z., Sawkar A.R., Whalen L.J., Wong C.-H., Kelly J.W. Isofagomine- and 2,5-anhydro-2,5-imino-d-glucitol-based glucocerebrosidase pharmacological chaperones for gaucher disease intervention. J. Med. Chem. 2007, 50:94-100.
60. Lieser M., Harms E., Kern H., Bach G., Cantz M. Ganglioside gm3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Ssubcellular distribution and some properties. Biochem. J. 1989, 260:69-74.
61. Ulrich-Bott B., Klem B., Kaiser R., Spranger J., Cantz M. Lysosomal sialidase deficiency: increased ganglioside content in autopsy tissues of a sialidosis patient. Enzyme 1987, 38:262-266.
62. Cantz M., Messer H. Oligosaccharide and ganglioside neuraminidase activities of mucolipidosis I (sialidosis) and mucolipidosis II (I-cell disease) fibroblasts. Eur. J. Biochem. 1979, 97:113-118.
63. Walkley S.U. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol. 2004, 15:433-444.
64. Schmid B., Paton B.C., Sandhoff K., Harzer K. Metabolism of gm1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (sap, saposin) 1 and prosaposin deficient disorders. Hum. Genet. 1992, 89:513-518.
65. Wang J., Wu G., Miyagi T., Lu Z.-H., Ledeen R.W. Sialidase occurs in both membranes of the nuclear envelope and hydrolyzes endogenous gd1a. J. Neurochem. 2009, 111:547-554.
66. Sciannamblo M., Chigorno V., Passi A., Valaperta R., Zucchi I., Sonnino S. Changes of the ganglioside pattern and content in human fibroblasts by high density cell population subculture progression. Glycoconj. J. 2002, 19:181-186.
67. Schwarzmann G. Uptake and metabolism of exogenous glycosphingolipids by cultured cells. Semin. Cell Dev. Biol. 2001, 12:163-171.
68. Charrow J., Binns H.J. Ganglioside loading of cultured fibroblasts: a provocative method for the diagnosis of the gm2 gangliosidoses. Clin. Chim. Acta 1986, 156:41-49.
69. Usuki S., Lyu S.C., Sweeley C.C. Sialidase activities of cultured human fibroblasts and the metabolism of gm3 ganglioside. J. Biol. Chem. 1988, 263:6847-6853.
70. Koul O., Prada-Maluf M., McCluer R.H., Ullman M.D. Rapid isolation of monosialogangliosides from bovine brain gangliosides by selective-overload chromatography. J. Lipid Res. 1991, 32:1712-1715.
71. Lutz M.S., Jaskiewicz E., Darling D.S., Furukawa K., Young W.W. Cloned beta 1,4 n-acetylgalactosaminyltransferase synthesizes ga2 as well as gangliosides gm2 and gd2. gm3 synthesis has priority over ga2 synthesis for utilization of lactosylceramide substrate in vivo. J. Biol. Chem. 1994, 269:29227-29231.
72. Sandhoff K., Kolter T. Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R Soc. Lond. B Biol. Sci. 2003, 358:847-861.
73. Hasegawa T., Sugeno N., Takeda A., Matsuzaki-Kobayashi M., Kikuchi A., Furukawa K., Miyagi T., Itoyama Y. Role of neu4l sialidase and its substrate ganglioside gd3 in neuronal apoptosis induced by catechol metabolites. FEBS Lett. 2007, 581:406-412.
74. Rauschert N., Brändlein S., Holzinger E., Hensel F., Müller-Hermelink H.-K., Vollmers H.P. A new tumor-specific variant of grp78 as target for antibody-based therapy. Lab. Invest. 2008, 88:375-386.
75. Kim T.W., Pettingell W.H., Hallmark O.G., Moir R.D., Wasco W., Tanzi R.E. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J. Biol. Chem. 1997, 272:11006-11010.
76. Rape M., Jentsch S. Taking a bite: proteasomal protein processing. Nat. Cell Biol. 2002, 4:E113-E116.
77. Bonuccelli G., Sotgia F., Capozza F., Gazzerro E., Minetti C., Lisanti M.P. Localized treatment with a novel fda-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 2007, 6:1242-1248.